Inventiva (ENXTPA:IVA) Refreshes Its Board, Is The 62% Discount Too Wide?
Inventiva (ENXTPA:IVA) has drawn fresh attention after appointing Dr. Barbara Krebs-Pohl, Dr. Anne Prener, and Camilla Soenderby as independent board members, a governance shift that could influence how investors think about the stock.
See our latest analysis for Inventiva.
At a share price of €3.82, Inventiva has seen a 14.89% 7 day share price return and an 11.70% 30 day share price return. However, the 90 day share price return is down 17.41%, while the 1 year total shareholder return of 38.41% contrasts with a weaker 5 year total shareholder return that is down 67.90%. This suggests that recent momentum has picked up after a tougher longer term journey.
If this kind of board level shift has caught your attention, it could be a good moment to broaden your watchlist with 129 healthcare AI stocks
Inventiva now trades at a sharp discount to analyst targets after its latest board refresh. Is that gap a sign the market is being too cautious, or a fair reflection of the risks around this clinical stage business?
Most Popular Narrative: 62.2% Undervalued
With Inventiva last closing at €3.82 against a narrative fair value of about €10.09, the most followed narrative sees a wide gap that rests on ambitious long term assumptions around its MASH program and funding runway.
The ongoing Phase III clinical trial for lanifibranor in MASH is anticipated to complete patient recruitment in the first half of 2025, with top-line results expected in the second half of 2026. This positions lanifibranor potentially as the second oral drug approved for MASH in the United States, which could significantly increase revenue.
Curious what has to happen between now and those trial readouts to support this fair value, including steep revenue ramps, changing margins and a premium future earnings multiple that few biotechs see for long.
Result: Fair Value of €10.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors should consider that revenues decreased from €17.5 million in 2023 to €9.2 million in 2024, and the company reported a €184.2 million net loss.
Find out about the key risks to this Inventiva narrative.
Next Steps
With mixed sentiment around Inventiva, you may want to review the same information and form your own view, starting with 1 key reward and 4 important warning signs
Looking for more investment ideas beyond Inventiva?
If Inventiva has you thinking more broadly about opportunities, do not stop here. Casting a wider net now could help you spot ideas others overlook.
- Target steady compounding by checking out companies that prioritize reliability and cash generation through the 464 dividend fortresses
- Hunt for potential bargains hiding in plain sight with the screener containing 503 high quality undiscovered gems
- Focus on financial resilience first and filter for companies that score well on strength and stability via the solid balance sheet and fundamentals stocks screener (418 results)
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com